重组Hsp90α对眼角膜上皮损伤的治疗作用
该研究在小鼠角膜上皮损伤模型中探究热休克蛋白90(Hsp90)的创面愈合治疗作用。结果显示Hsp90α在角膜损伤后mRNA和蛋白水平上调并分泌至角膜基质和泪膜,外源性重组Hsp90α可加速角膜上皮创面愈合,其机制涉及结合LRP-1并增加AKT S473磷酸化。作者认为重组Hsp90α可能是角膜损伤有前景的治疗候选药物。
要点
- 小鼠角膜损伤后Hsp90α在mRNA和蛋白水平上调,并分泌至角膜基质和泪膜。
- 外源性重组Hsp90α可加速损伤角膜上皮的创面愈合。
- eHsp90α结合角膜上皮细胞LRP-1并增加AKT S473磷酸化,促进细胞增殖和迁移。
核心结论
- Hsp90α在角膜损伤后上调并分泌,发挥促进愈合过程的作用,重组Hsp90α可能是角膜损伤有前景的治疗候选药物。
研究设计与样本
- 研究对C57BL/6N雄性小鼠右眼角膜中央使用algerbrush II刀片行清创损伤,用荧光素钠染色和Image-J测定损伤面积。
- 采用免疫印迹、ELISA和免疫化学测定蛋白表达,实时定量PCR测定mRNA表达。
主要发现
- 小鼠角膜损伤愈合过程中Hsp90α在mRNA和蛋白水平上调,并分泌至角膜基质和泪膜,该上调与HSF1激活相关。
- 给予外源性重组Hsp90α(eHsp90α)可加速损伤角膜上皮的创面愈合。
- eHsp90α结合角膜上皮细胞上的低密度脂蛋白(LDL)相关蛋白-1(LRP-1)并增加AKT S473磷酸化,与体内外角膜上皮细胞增殖和迁移相关。
- 用AKT抑制剂LY294002抑制AKT可消除eHsp90α诱导的角膜上皮细胞迁移和增殖。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to explore the therapeutic role of heat shock protein 90 (Hsp90) in wound healing of injury cornea epithelium. METHODS: The right eye of C57BL/6N male mice were performed the debridement wounds in the center of the cornea using an algerbrush II blade. The injured area was determined by staining the cornea with fluorescein sodium and measured with image-J. Immunoblotting, ELISA and immunochemistry were used for determining protein expression. The quantitation PCR was performed to measure mRNA expression. RESULTS: Hsp90α is upregulated at both the mRNA and protein levels, and is secreted extracellularly into the corneal stroma and tear film during the healing process after corneal injury in mice. This upregulation is associated with activation of HSF1. Administration of recombinant exogenous Hsp90α (eHsp90α) speeds up wound healing of injured corneal epithelium. The eHsp90α binds to low-density lipoprotein (LDL)-related protein-1 (LRP-1) on the corneal epithelial cells and increases phosphorylation of AKT at S473, which is associated with proliferation and migration corneal epithelial cells in vitro or vivo. Inhibition of AKT by its inhibitor LY294002 abolishes eHsp90α-induced migration and proliferation of corneal epithelial cells. CONCLUSION: Hsp90α is upregulated and secreted after corneal injury and acts to promote the healing process. Recombinant Hsp90α may be a promising therapeutic drug candidate for corneal injury.
引用
- Wang M, Hu J, Qu J, et al. The Therapeutic Roles of Recombinant Hsp90α on Cornea Epithelial Injury. Invest Ophthalmol Vis Sci. 2022. PMID: 35201262. doi:10.1167/iovs.63.2.30
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。